Systematic Review: What CBD Does (and Does Not) Do in Humans | Research

The takeaway

A systematic review of 34 human studies found preliminary evidence that high-dose oral CBD (150-600 mg/day) may help with social anxiety, insomnia, and epilepsy, while CBD's interaction with THC varied depending on route of administration.

Read this if you want a research-grounded overview of what CBD actually does in humans.

150-600 mg/day oral CBD showed therapeutic signals for anxiety, insomnia, and epilepsy

What the researchers found

The review identified 34 studies: 16 in healthy subjects and 18 in clinical populations covering MS, schizophrenia, bipolar mania, social anxiety, pain, cancer, Huntington's disease, insomnia, and epilepsy.

Key findings included: high inhaled/IV doses of CBD were needed to block THC effects. Oral/oromucosal CBD sometimes prolonged or intensified THC effects (contradicting the common belief that CBD always counteracts THC). Preliminary clinical evidence supported CBD for social anxiety disorder, insomnia, and epilepsy at doses of 150-600 mg/day, but mental sedation was a concern.

Why it matters

This was one of the first comprehensive systematic reviews of CBD's effects in humans, providing a reality check on both the hype and skepticism surrounding CBD. The finding that CBD can sometimes enhance rather than counteract THC is particularly important for patients using combination products.

The numbers in context

34 studies reviewed (16 experimental, 18 clinical). Clinical conditions: MS (6), schizophrenia/bipolar (4), social anxiety (2), pain (2), cancer anorexia (1), Huntington's (1), insomnia (1), epilepsy (1). Therapeutic dose range: 150-600 mg/day oral.

How the study worked

Systematic review searching PubMed and EMBASE for "cannabidiol." Included randomized and crossover studies in healthy controls and clinical patients. Both CBD monotherapy and CBD+THC combination studies were included. 34 studies met inclusion criteria.

What this study cannot tell us

Many of the included studies had small sample sizes. The clinical studies covered diverse conditions with different designs, making synthesis difficult. The review captured a relatively early stage of CBD clinical research when few large trials had been conducted.

How to read the evidence

Systematic review of 34 studies; provides moderate evidence though many included studies were small.

When this study was published

Published in 2012. CBD research has expanded enormously since, with FDA-approved Epidiolex for epilepsy and ongoing trials for other conditions.

The bigger picture

This review captured CBD research at an inflection point. By 2012, enough human data existed to see genuine therapeutic signals, but the evidence was preliminary and the dose-response relationships were complex. The review set the stage for the larger clinical trials that followed.

Questions still open

What are the optimal CBD doses for each therapeutic indication? Why does the route of administration change how CBD interacts with THC? Is the sedation at high doses a side effect or a therapeutic feature for conditions like insomnia?

Common questions

Does CBD counteract THC?

It is more complicated than commonly believed. This review found that inhaled or IV CBD at high doses can block THC effects, but oral or oromucosal CBD sometimes prolonged or intensified THC effects. The interaction depends on the route of administration, doses, and timing.

What conditions does CBD actually help with?

As of this 2012 review, the strongest preliminary evidence was for social anxiety disorder, insomnia, and epilepsy, all using high oral doses (150-600 mg/day). Evidence for other conditions existed but was more limited. Since this review, CBD (as Epidiolex) has been FDA-approved for certain epilepsy types.

Read the original research

Cannabidiol in humans-the quest for therapeutic targets.

Pharmaceuticals (Basel, Switzerland), 5(5), 529-52

View on PubMed ↗Publisher’s paper ↗

Citation

Zhornitsky, Simon; Potvin, Stéphane. (2012). Cannabidiol in humans-the quest for therapeutic targets.. Pharmaceuticals (Basel, Switzerland), 5(5), 529-52. https://doi.org/10.3390/ph5050529